AbbVie cuts Editas CRISPR pact it inherited from Allergan Biogen nabs speedy FDA review for controversial Alzheimer’s drug Levo Therapeutics’ Prader-Willi med fizzles in phase 3, but company presses on Autolus CMO Peddareddigari departs to return to the US Fauci: Political pressure won’t interfere with FDA decisions on COVID-19 vaccines NIH launches imaging AI collaboration for COVID-19 and beyond How a protein promotes pancreatic cancer metastasis FiercePharmaAsia—COVID vax deals by AstraZeneca in China, Pfizer-BioNTech in Japan; new Legend CEO Chutes & Ladders—Alexion names Qadeer as first chief diversity officer Featured Story | By Ben Adams Editas Medicine’s shares fell by nearly 4% afterhours when Allergan’s new owner AbbVie decided to end a deal originally penned under its buyout with the gene-editing biotech. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Biogen’s aducanumab is inching closer to an FDA decision. The Big Biotech, along with partner Eisai, announced on Friday that the FDA accepted its regulatory submission for aducanumab, its once-failed Alzheimer’s drug—with priority review to boot. The agency expects to decide the fate of the treatment by March 7, 2021. read more By Amirah Al Idrus The higher dose of Levo Therapeutics’ lead candidate failed to beat placebo in a phase 3 study of Prader-Willi syndrome, a debilitating genetic disorder that causes insatiable hunger and obesity. However, the lower dose did better, leading the company to switch all patients in the trial to that dose. read more By Nick Paul Taylor Autolus chief medical officer (CMO) Vijay Peddareddigari is leaving the company to return to the U.S. The British CAR-T biotech disclosed the departure alongside news that Nushmia Khokhar, who crossed paths with Peddareddigari at Johnson & Johnson, has stepped up to a clinical SVP position. read more By Nick Paul Taylor The FDA has vowed not to let political pressure to approve a COVID-19 vaccine as soon as possible interfere with the regulatory process, Anthony Fauci told Reuters. Fauci’s comments come ahead of an election season in which the availability of a vaccine could influence the vote. read more By Conor Hale The NIH is turning to AI and medical imaging to not only detect cases of COVID-19 earlier, but to help personalize treatments for the spreading disease. read more By Angus Liu While studying how pancreatic cancer adapts to a low-oxygen environment, scientists at Sanford Burnham Prebys Medical Discovery Institute uncovered a protein that appeared to be driving tumor metastasis, opening up a potential new venue in developing drugs against the deadly disease read more By Angus Liu AstraZeneca grants BioKangtai China rights to its COVID-19 vaccine, with a goal for annual production capacity of 200 million doses. Pfizer and BioNTech will provide 120 million doses of their COVID-19 mRNA vaccine to Japan in early 2021. Genscript chief stepped into Legend Biotech's CEO role. read more By Eric Sagonowsky Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite. Melinta Therapeutics also named a new CEO. read more Enrollment Showcase | Presented by: Biotility Taught by experienced professionals, Biotility’s online short courses provide the knowledge and practical skills valued by the bioscience industry. Enhance your career through coursework in one of our certificate pathways, including Document Management, Operations Management, and Quality Management. Learn more. |
| |
|---|
|
Resources Sponsored by: Acorn AI by Medidata, a Dassault Systèmes company Case Study: Oncology-focused pharmaceutical company strengthens product launch by identifying hundreds of high-value physicians with Acorn AI. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Lonza Pharma & Biotech A novel spray-dried dispersion platform has been developed to faciliate high drug load applications Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. 18th Annual Discovery on Target Virtual September 16-18, 2020 Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now. | COVID19 provisions – training will be on-site as normal. | New – may be possible for some individuals to access the training virtually in real time. | 